Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Olink reports fourth quarter and full year 2022 financial results

UPPSALA, Sweden, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2022.

Highlights

  • Fourth quarter revenue totaled $57.9 million, representing year over year growth of 33% on a reported basis and 37% on a constant currency adjusted like-for-like basis
  • Full year 2022 revenue totaled $139.8 million, achieving year over year growth of 47% on a reported basis and 53% on a constant currency adjusted like-for-like basis
  • Total Explore customer installations reached 52, with 12 installations during the fourth quarter, and more than doubling during 2022 compared to 2021
  • Signature Q100 placements reached 91, with 28 placements during the fourth quarter, and more than tripling during 2022 compared to 2021
  • Explore revenue of $43.2 million accounted for 75% of total fourth quarter revenue, with Explore Kit revenue totaling $25.1 million, or 58% of total Explore revenues
  • Fourth quarter Kit revenue and analysis services revenue represented 53% and 40% of total revenue, respectively
  • Fourth quarter 2022 net income was $5.4 million, with adjusted EBITDA of $14.9 million compared to fourth quarter 2021 net loss of ($8.0) million and adjusted EBITDA of ($1.4) million
  • Raised $95 million in additional capital after the close of the fourth quarter 2022
  • Olink expects 2023 full year reported revenue to be in the range of $192 million to $200 million, representing growth of approximately 37% to 43% on a reported basis, and growth of approximately 38% to 44% on a constant currency basis; and expects the Company will return to profitability in 2023, as measured by EBITDA excluding share-based compensation expenses

“Olink enters 2023 with considerable business momentum across its entire customer base, and will continue to operate with science-driven thinking, customer-focused product innovation, and strong commercial execution,” said Jon Heimer, CEO of Olink. “Olink exited 2022 with record-setting Explore installations and strong Signature placements, as well as robust revenue growth. We anticipate 2023 will be another year of market-leading innovation and strong growth as we make further progress in developing the nascent and promising field of modern proteomics.”

Fourth quarter and full year financial results
“Our robust performance and strong financial profile are enabled by focused investment and disciplined spending into areas with significant opportunities to provide a strong return for Olink,” said Oskar Hjelm, CFO of Olink. "We are executing on our strategy to maximize the substantial commercial opportunity in proteomics and return to profitability, providing an excellent platform for long-term revenue and profit growth.”

Total revenue for the fourth quarter of 2022 was $57.9 million, as compared to $43.7 million for the fourth quarter of 2021, which represents reported growth of 33%, driven primarily by the strength in Explore. Reported full year 2022 revenue grew 47% to $139.8 million, as compared to $95.0 million for 2021.

Kits revenue for the fourth quarter of 2022 grew 100% to $30.6 million, or 53% of total revenue, as compared to $15.3 million for the fourth quarter of 2021, or 35% of total revenue, driven by strength in Explore, as well as Target. Full year 2022 kits revenue grew 106%, totaling $55.1 million, versus $26.8 million during 2021.

Analysis services revenue for the fourth quarter of 2022 was $23.4 million, as compared to $23.7 million for the fourth quarter of 2021, in line with Olink’s goal of driving product mix toward kits. Year-over-year analysis services revenue declined 1% in the fourth quarter on a reported basis, but grew approximately 30% when adjusting for completion of the UK Biobank Pharma Proteomics Project (UKB-PPP). Full year 2022 analysis service revenue totaled $73.0 million, versus $60.2 million for 2021, representing 21% growth.

Other revenue was $3.9 million for the fourth quarter of 2022, as compared to $4.7 million for the fourth quarter of 2021. Full year 2022 other revenue totaled $11.7 million, versus $8.0 million for 2021.

By geography, revenue during the fourth quarter of 2022 was $31.9 million in North America, $20.0 million in EMEA (including Sweden), and $6.0 million in China and RoW (including Japan). Year-over-year revenue in EMEA (including Sweden) decreased 1% in the fourth quarter on a reported basis, and grew approximately 39% when adjusting for completion of the UKB-PPP. By geography, revenue during the full year 2022 was $66.5 million in North America, $57.7 million in EMEA (including Sweden), and $15.6 million in China and RoW (including Japan).

Net income was $5.4 million for the fourth quarter of 2022 and adjusted EBITDA was $14.9 million, as compared to a net loss of ($8.0) million and adjusted EBITDA of ($1.4) million for the fourth quarter of 2021. Full year 2022 net loss was ($12.9) million and adjusted EBITDA was ($3.9) million, versus a net loss of ($38.3) million and adjusted EBITDA of ($18.5) million for 2021.

Consolidated gross profit was $43.1 million in the fourth quarter of 2022, as compared to $25.3 million in the fourth quarter of 2021. Full year 2022 gross profit totaled $94.5 million, versus $58.2 million for 2021. Consolidated adjusted gross profit was $44.0 million in the fourth quarter of 2022, as compared to $26.5 million in the fourth quarter of 2021. Full year 2022 adjusted gross profit totaled $97.9 million, versus $61.3 million for 2021.

By segment, adjusted gross profit margin for kits was 87.6% for the fourth quarter of 2022, as compared to 85.1% for the fourth quarter of 2021; and reported gross profit margin for kits was 86.9% for the fourth quarter of 2022, as compared to 84.0% for the fourth quarter of 2021. Full year 2022 adjusted gross profit margin for kits was 88.4%, versus 86.4% for 2021; and full year 2022 reported gross profit margin for kits was 87.1%, versus 84.7% for 2021.

Adjusted gross profit margin for analysis services was 66.9% for the fourth quarter of 2022, as compared to 50.2% for the fourth quarter of 2021; and reported gross profit margin for analysis services was 64.1% for the fourth quarter of 2022, as compared to 45.9% for the fourth quarter of 2021. The increase in analysis services margin in the fourth quarter of 2022 compared to 2021 was related to the completion of the UKB-PPP earlier in the year as well as improved operational efficiency in the labs. Full year 2022 adjusted gross profit margin for analysis services was 60.1%, versus 57.3% for 2021; and full year 2022 reported gross profit margin for analysis services was 56.5%, versus 53.0% for 2021.

Adjusted and reported gross profit margin for Other was 40.6% for the fourth quarter of 2022, as compared to 34.1% for the fourth quarter of 2021. Full year 2022 adjusted and reported gross profit margin for Other was 45.2%, versus 45.3% for 2021.

Total operating expenses for the fourth quarter of 2022 were $34.9 million, as compared to $33.1 million for the fourth quarter of 2021. Full year 2022 total operating expenses were $125.1 million, as compared to $102.9 million for 2021. The increase in full year 2022 was largely due to continued investment in Olink's commercial organization and research and development and driven by additional costs as a public company as well.

Net income for the fourth quarter of 2022 was $5.4 million, as compared to a net loss of ($8.0) million for the fourth quarter of 2021. Full year 2022 net loss totaled ($12.9) million, as compared to ($38.3) million for 2021.

Net income per share for the fourth quarter of 2022 was $0.05 based on a weighted average number of outstanding shares of 119,943,003 as compared to a net loss per share of ($0.07) in the fourth quarter of 2021 based on a weighted average number of outstanding shares of 119,007,062. Full year 2022 net loss per share totaled ($0.11), versus ($0.43) per share in 2021.

2023 guidance
Olink expects 2023 full year reported revenue to be in the range of $192 million to $200 million, representing growth of approximately 37% to 43% on a reported basis, and growth of approximately 38% to 44% on a constant currency basis.

The Company also expects revenues in 2023 will continue to progress along a seasonal pattern that is weighted toward the second half of the year, and fourth quarter specifically. In addition, Olink believes with continued growth and scale up, it will return to profitability in 2023, as measured by EBITDA excluding share-based compensation expenses.

Webcast and conference call details
Company management will host a conference call to discuss financial results at 8:00 am ET. Investors interested in listening to the conference call are required to register online here. A live webcast will be available in the “Events” section of the Company's website at https://investors.olink.com/investor-relations. The webcast will be archived and available for replay for at least 90 days after the event.

Statement regarding use of non IFRS financial measures
We present certain non-IFRS financial measures because they are used by our management to evaluate our operating performance and formulate business plans. We believe that the use of these non-IFRS measures facilitates investors’ assessment of our operating performance. We caution readers that amounts presented in accordance with our definitions of adjusted EBITDA, adjusted gross profit, adjusted gross profit margin, adjusted gross profit margin by segment, and constant currency revenue growth, may not be the same as similar measures used by other companies. Not all companies and Wall Street analysts calculate the non-IFRS measures we use in the same manner. We compensate for these limitations by reconciling each of these non-IFRS measures to the nearest IFRS performance measure, which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure.

We are not able to forecast constant currency revenue on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in predicting foreign currency exchange rates and, as a result, are unable to provide a reconciliation to forecasted constant currency revenue.

Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com

Forward-looking statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our 2023 revenue outlook, our Explore externalizations, our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the caption "Risk Factors" in our Form 20-F (Commission file number 001-40277) and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections for the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.


INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

 Three months ended December 31,Twelve months ended December 31,
 
Amounts in thousands of U.S. Dollars 2022  2021  2022  2021 
Revenue$57,885 $43,683 $139,848 $94,973 
Cost of goods sold (14,760) (18,379) (45,349) (36,763)
Gross profit$ 43,125 $ 25,304 $ 94,499 $ 58,209 
Selling expenses (13,379) (11,950) (44,673) (33,668)
Administrative expenses (13,882) (11,826) (54,274) (47,495)
Research and development expenses (6,584) (8,722) (26,345) (22,141)
Other operating income (1,102) (596) 191  443 
Operating (loss)/income$ 8,178 $ (7,791)$ (30,602)$ (44,652)
Interest income 1,119  98  1,159  98 
Interest expense (124) (136) (531) (2,146)
Foreign exchange, net (2,847) 2,523  14,059  1,875 
Other financial income/(expenses) 508  19  508  (1,719)
(Loss)/income before tax 6,834  (5,288) (15,407) (46,545)
Income tax benefit/(expense) (1,404) (2,685) 2,556  8,206 
Net (loss)/income for the period (Attributable to shareholders of the Parent)$ 5,430 $ (7,972)$ (12,851)$ (38,339)
Other comprehensive (loss)/income:    
Items that may be reclassified to profit or loss:    
Exchange differences from translation of foreign operations 23,772  (13,570) (60,606) (37,659)
Other comprehensive (loss)/income for the period, net of tax 23,772  (13,570) (60,606) (37,659)
Total comprehensive (loss)/income for the period, net of tax$29,202 $(21,542)$(73,457)$(75,998)
Total comprehensive (loss)/income for the period (Attributable to shareholders of the Parent)$ 29,202 $ (21,542)$ (73,457)$ (75,998)
Basic and diluted (loss)/income per share$ 0.05 $ (0.07)$ (0.11)$ (0.43)
     


INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED)

Amounts in thousands of U.S. DollarsAs of December 31, 2022As of December 31, 2021
ASSETS  
Non-current assets  
Intangible assets 257,480  308,124 
Property, plant and equipment 15,056  12,696 
Right-of-use asset 9,891  8,778 
Deferred tax assets 10,846  9,091 
Other long-term receivables 571  422 
Total non-current assets$ 293,844 $ 339,111 
Current assets  
Inventories 44,246  28,940 
Trade receivables 52,743  42,061 
Other receivables 2,562  4,094 
Prepaid expenses and accrued income 7,786  7,476 
Cash at bank and in hand 75,109  118,096 
Total current assets$ 182,446 $ 200,667 
TOTAL ASSETS$ 476,290 $ 539,778 
EQUITY  
Share capital 30,988  30,964 
Other contributed capital 514,133  506,008 
Reserves/(Deficit) (58,581) 1,701 
Accumulated Deficit (75,855) (62,997)
Total equity attributable to shareholders of the Parent$ 410,685 $ 475,676 
LIABILITIES  
Non-current liabilities  
Lease liabilities 7,322  5,427 
Deferred tax liabilities 22,196  27,092 
Total non-current liabilities$ 29,518 $ 32,519 
Current liabilities  
Lease liabilities 2,113  2,952 
Accounts payable 6,885  8,668 
Current tax liabilities 1,389  314 
Other current liabilities 25,700  19,649 
Total current liabilities$36,087 $
31,583 
Total liabilities$ 65,605 $ 64,102 
TOTAL EQUITY AND LIABILITIES$ 476,290 $ 539,778 
   


INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

 Twelve months ended December 31, 
Amounts in thousands of U.S. Dollars 2022  2021  
Operating activities   
Loss before tax$(15,407)$(46,545) 
Adjustments reconciling loss before tax to operating cash flows:   
  Depreciation and amortization 17,326  15,802  
  Net finance (expense)/income (15,164) 1,893  
  Loss on sale of assets 465  502  
  Share-based compensation expense 7,907  2,524  
  Other 233    
Changes in working capital:   
  (Increase) in inventories (18,934) (10,158) 
  (Increase) in accounts receivable (13,867) (12,172) 
  (Increase) in other current receivables (1,950) (6,105) 
  (Decrease)/Increase in trade payables (751) 3,014  
  Increase in other current liabilities 7,643  2,039  
Interest received 1,159  98  
Interest paid (531) (2,312) 
Other finance income 508    
Tax received/(paid) 1,297  (2,266) 
Cash flow used in operating activities$ (30,066)$ (53,687) 
Investing activities   
Purchase of intangible assets (1,378) (4,325) 
Purchase of property, plant and equipment (7,173) (10,482) 
Proceeds from sale of property, plant and equipment   144  
(Increase) in other non-current financial assets (162) (297) 
Cash flow used in investing activities$ (8,713)$ (14,960) 
Financing activities   
Proceeds from issue of share capital 24  264,706  
Share issue costs   (19,484) 
Proceeds from interest-bearing loans and borrowings   2,312  
Repayment of interest-bearing loans and borrowings   (65,627) 
Payment of principal portion of lease liability (2,908) (2,845) 
Cash flow (used in)/from financing activities$ (2,884)$ 179,062  
Net cash flow during the period (41,663) 110,415  
Cash at bank and in hand at the beginning of the period 118,096  8,656  
Net foreign exchange difference (1,324) (975) 
Cash at bank and in hand at the end of the period$ 75,109 $ 118,096  
    


Reconciliations of adjusted gross profit to gross profit, the most directly comparable IFRS measure, by segment (unaudited):

  Three months ended December 31,Twelve months ended December 31,
Amounts in thousands of U.S. Dollars unless otherwise stated 2022  2021  2022  2021 
Kit    
Revenue 30,555  15,263  55,091  26,797 
Cost of goods sold (4,011) (2,439) (7,131) (4,112)
Gross profit$ 26,544 $ 12,824 $ 47,960 $ 22,685 
Gross profit margin 86.9% 84.0% 87.1% 84.7%
Less:    
Depreciation charges 157  114  569  431 
Share-based compensation expenses 57  48  176  48 
Adjusted Gross Profit$ 26,758 $ 12,986 $ 48,705 $ 23,164 
Adjusted Gross Profit % 87.6% 85.1% 88.4% 86.4%
     
Service    
Revenue 23,389  23,693  73,012  60,221 
Cost of goods sold (8,407) (12,826) (31,776) (28,299)
Gross profit$ 14,982 $ 10,867 $ 41,236 $ 31,922 
Gross profit margin 64.1% 45.9% 56.5% 53.0%
Less:    
Depreciation charges 563  986  2,448  2,561 
Share-based compensation expenses 105  52  220  52 
Adjusted Gross Profit$ 15,650 $ 11,905 $ 43,904 $ 34,535 
Adjusted Gross Profit % 66.9% 50.2% 60.1% 57.3%
     
Corporate / Unallocated    
Revenue 3,940  4,727  11,745  7,955 
Cost of goods sold (2,342) (3,115) (6,442) (4,352)
Gross profit$ 1,598 $ 1,612 $ 5,303 $ 3,603 
Gross profit margin 40.6% 34.1% 45.2% 45.3%
Less:    
Depreciation charges        
Share-based compensation expenses        
Adjusted Gross Profit$ 1,598 $ 1,612 $ 5,303 $ 3,603 
Adjusted Gross Profit % 40.6% 34.1% 45.2% 45.3%
     


Reconciliation of constant currency revenue growth to revenue growth as reported under IFRS, the most directly comparable IFRS measure (unaudited):

We use the non-IFRS measure of constant currency growth, which we define as our total revenue growth from one fiscal year to the next on a constant currency exchange rate basis. We measure our constant currency revenue growth by applying the current fiscal period’s average exchange rate to the prior year fiscal period.

 Three months ended December 31,Twelve months ended December 31,
Amounts in thousands of U.S. Dollars, unless otherwise stated2022 20212022 2021
Revenue57,885 43,683139,848 94,973
  Revenue growth (IFRS)33% 47% 
  Foreign exchange impact-4% -6% 
Constant currency revenue growth37% 53% 
     


Reconciliation of consolidated adjusted gross profit to gross profit, the most directly comparable IFRS measure (unaudited):

 Three months ended December 31,Twelve months ended December 31,
Amounts in thousands of U.S. Dollars, unless otherwise stated2022 2021 2022 2021 
Revenue57,885 43,683 139,848 94,973 
Cost of goods sold(14,760)(18,379)(45,349)(36,763)
Gross Profit43,125 25,304 94,499 58,210 
Gross Profit %74.5%57.9%67.6%61.3%
Less:    
Depreciation charges720 1,100 3,017 2,992 
Share-based compensation expenses162 100 396 100 
Adjusted Gross Profit44,007 26,504 97,912 61,302 
Adjusted Gross Profit %76.0%60.7%70.0%64.5%
     


Reconciliation of adjusted EBITDA to operating loss, the most directly comparable IFRS measure (unaudited):

 Three months ended December 31,Twelve months ended December 31,
Amounts in thousands of U.S. Dollars20222021 2022 2021 
Operating income/(loss)8,178(7,791)(30,602)(44,652)
Add:    
Amortization2,6822,993 11,212 11,090 
Depreciation1,6101,635 6,114 4,713 
EBITDA12,470(3,163)(13,276)(28,849)
Management Adjustments298(85)1,288 7,777 
Share-based compensation expenses2,0841,888 8,047 2,524 
Adjusted EBITDA14,852(1,360)(3,941)(18,548)
     

Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.